Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quanex To Contact Him Directly To Discuss Their Options If you suffered losses in Quanex between December 12, 2024 and September 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Cytokinetics To Contact Him Directly To Discuss Their Options If you suffered losses in Cytokinetics between December 27, 2023 and May 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & Faruqi ...

Core Viewpoint - A securities class action lawsuit has been filed against V.F. Corporation, with a deadline for lead plaintiff applications set for November 12, 2025, for investors who acquired VFC securities between October 30, 2023, and May 20, 2025 [1][2]. Company Information - V.F. Corporation and certain executives are accused of failing to disclose material information during the class period, which constitutes a violation of federal securities laws [3]. - The company reported a significant decline in its Vans brand growth, with losses increasing from 8% to 20% in the fourth quarter of fiscal 2025, attributed to deliberate revenue reductions to eliminate unprofitable businesses [4]. Market Reaction - Following the announcement of the financial results, V.F. Corporation's share price dropped from $14.43 on May 20, 2025, to $12.15 on May 21, 2025, marking a decline of approximately 15.8% in one day [5].

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PubMatic To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in PubMatic between February 27, 2025 and August 11, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330Â (Ext. 1310). To learn more about the PubMatic class acti ...

Accessibility StatementSkip Navigation Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lockheed Martin To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lockheed Martin between January 23, 2024 and July 21, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247- 4292 or 212-983-9330Â (Ext. 1310). [You may also click here for ad ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against CTO Realty Growth, Inc. due to allegations of misleading statements regarding the sustainability of dividends and financial practices, with a deadline for investors to seek lead plaintiff status by October 7, 2025 [1][3]. Group 1: Allegations Against CTO Realty Growth - The complaint alleges that CTO and its executives violated federal securities laws by making false statements and failing to disclose that CTO's dividends were less sustainable than claimed [3]. - The company reportedly used deceptive practices to inflate its Adjusted Funds From Operations (AFFO) and overstate the profitability of its Ashford Lane property [3]. - The Wolfpack Research report criticized CTO for not generating enough cash to cover its recurring capital expenditures and dividends since converting to a REIT in 2021, indicating reliance on share dilution to cover a $38 million dividend shortfall [4]. Group 2: Financial Impact and Stock Performance - Following the release of the Wolfpack Report, CTO's stock price fell by $0.98, or 5.42%, closing at $17.10 per share on June 25, 2025 [5]. - The report highlighted that CTO has only $8.4 million in cash while facing quarterly dividends of $14 million and average recurring capital expenditures of $5.7 million, suggesting imminent further dilution [4]. Group 3: Legal Proceedings and Investor Actions - Investors who suffered losses exceeding $75,000 in CTO between February 18, 2021, and June 24, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1]. - The firm is seeking to appoint a lead plaintiff who has the largest financial interest in the relief sought by the class, with any member able to move the court to serve as lead plaintiff [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Fiserv, Inc. related to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by September 22, 2025 [4]. Group 1: Allegations Against Fiserv - The complaint alleges that Fiserv and its executives made false and misleading statements regarding the performance of its Clover platform, particularly in relation to forced migrations from the older Payeezy platform [6]. - It is claimed that Clover's revenue growth and gross payment volume (GPV) were artificially inflated due to these forced conversions, masking a slowdown in new merchant business [6]. - Following the forced migrations, many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's GPV growth [6]. Group 2: Market Reaction and Stock Performance - On April 24, 2025, Fiserv reported a GPV growth of only 8% for Q1 2025, a decline from 14-17% in 2024, resulting in an 18.5% drop in stock price to $176.90 [7]. - On May 15, 2025, Fiserv announced that GPV growth deceleration would continue throughout 2025, causing a further 16.2% decline in stock price to $159.13 [7]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a deceleration in quarterly organic revenue growth to 9% year-over-year, leading to a 13.9% drop in stock price to $143.00 [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Charter Communications, Inc. due to allegations of violations of federal securities laws, particularly related to misleading statements about the company's performance and the impact of the Affordable Connectivity Program (ACP) ending [4][6]. Group 1: Legal Investigation and Claims - The firm is encouraging investors who suffered losses exceeding $100,000 in Charter between July 26, 2024, and July 24, 2025, to contact them for discussions about their legal rights [1][4]. - There is a deadline of October 13, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Charter [4][8]. - The complaint alleges that Charter and its executives made false or misleading statements regarding the company's ability to manage the impact of the ACP ending and its overall business performance [6][7]. Group 2: Financial Performance and Market Reaction - Charter reported a decline of 117,000 total internet customers in Q2 2025, compared to a decline of about 100,000 in Q2 2024, after adjusting for the ACP's prior year's impact [7]. - The company's total video customers also decreased by 80,000 during the same period [7]. - Following the release of these financial results, Charter's stock price fell by $70.25 per share, or 18.5%, closing at $309.75 per share on July 25, 2025 [7]. Group 3: Company Background and Contact Information - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [5]. - The firm is actively seeking information regarding Charter's conduct from whistleblowers, former employees, shareholders, and others [9][10].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Unicycive Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements about the company's compliance with FDA manufacturing requirements and the regulatory prospects of its New Drug Application (NDA) for OLC [4][6]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Unicycive between March 29, 2024, and June 27, 2025, to contact them for legal options [1]. - There is a deadline of October 14, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Unicycive [4]. - The complaint alleges that Unicycive and its executives made false and misleading statements regarding the company's readiness to meet FDA manufacturing compliance requirements and the prospects of the OLC NDA [6]. Group 2: Stock Price Impact - Following a press release on June 10, 2025, regarding FDA deficiencies at a third-party manufacturing vendor, Unicycive's stock price fell by $3.68 per share, or 40.89%, closing at $5.32 per share [7]. - On June 30, 2025, after the FDA issued a Complete Response Letter for the OLC NDA due to the same deficiencies, the stock price dropped by $2.03 per share, or 29.85%, closing at $4.77 per share [8]. Group 3: Class Action Participation - The lead plaintiff in a class action is defined as the investor with the largest financial interest who is adequate and typical of class members, overseeing the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against LifeMD, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and financial guidance [4][6]. Group 1: Legal Investigation - The law firm is encouraging investors who suffered losses exceeding $75,000 in LifeMD between May 7, 2025, and August 5, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against LifeMD, with a deadline of October 27, 2025, for investors to seek the role of lead plaintiff [4][8]. Group 2: Allegations Against LifeMD - The complaint alleges that LifeMD and its executives materially overstated the company's competitive position and were reckless in raising the 2025 guidance without properly accounting for rising customer acquisition costs [6]. - LifeMD's revised guidance announced on August 5, 2025, projected total revenue in the range of $250 to $255 million, down from previous guidance of $268 to $275 million, leading to a 44.8% stock price drop on August 6, 2025 [7].